Skip to main content
Loading...
Menu social network
LinkedIn
Facebook
X
Youtube
Menu top
Assistance
User account menu
Log in
Main navigation
Home
Programme
Download the app
App
Download the app
App
Menu
Login
Close
Main navigation mobile
Home
Programme
Menu top
Assistance
Menu social network
LinkedIn
Facebook
X
Youtube
38 results
D1.50 - Allergic Bronchopulmonary Aspergillosis in a Tertiary Allergy Center: Clinical Characteristics, Radiologic Subtypes, and Biologic Use
D1.54 - Latex-Induced Occupational Asthma: An Underrecognized Hazard in the Electronics and Cable Industry
D1.46 - Molecular patterns of fungal sensitization in patients with asthma and allergic rhinitis: evidence from real-life clinical practice
D1.47 - Assessment of Asthma Control in Elderly Patients Using Forced Oscillation Technique, Spirometry, and Asthma Control Test in Relation to GINA Classification
D1.48 - Early-Onset Multiorgan Allergic Phenotype with Transformation into Controlled Asthma in a 2-Year-Old Child: The Role of Molecular Diagnostics (ALEX²) in Risk Stratification
D1.49 - Component-Resolved Pet Allergen Sensitization Identifies Adolescents With Airway Inflammation and Bronchial Hyperresponsiveness
D1.51 - Evaluation of the Correlation Between Skin Prick Test, Specific Immunoglobulin E Levels and Clinical Findings in Children with Cat Allergen Sensitization
D1.52 - The Borg Fallacy in Olympic Athletes: Symptom Perception Fails to Identify Airway Hyperresponsiveness
D1.55 - Monosensitization to Der p 23 in house dust mite allergy in daily clinical practice in a county of Gipuzkoa, Basque Country, Spain: a retrospective and descriptive analysis
D1.57 - New allergens registered in the WHO/IUIS Allergen Database in 2025: new and old foes
D1.58 - “Evaluation of Chronic Cough in Patients with Allergic Disease, GERD, and Chronic Rhinosinusitis”
D1.60 - Clinical Characteristics of Children with Patch Test–Positive Allergic Contact Dermatitis: Effects of Treatment on Quality of Life
D1.437 - A Decade of Research on Janus Kinase Inhibitors in Atopic Dermatitis: A Global Bibliometric Analysis (2015–2024)
D1.438 - Dupilumab for Moderate-to-Severe Atopic Dermatitis in Children and Adolescents: Real-Life Assessment of Efficacy and Safety
D1.442 - Design and Preclinical Development of a Bispecific Antibody Targeting IL11 and TL1A
D1.443 - Preclinical Development of a Dual LIGHT/TL1A Bispecific Antibody
D1.446 - Lebrikizumab in patients with urticarial vasculitis - a case series
D1.447 - Comparison of Disease Duration, Remission, and Other Disease-Related Parameters with the Duration of Omalizumab Treatment in Patients with Chronic Spontaneous Urticaria
D1.448 - Long-Term Efficacy and Stability of Lebrikizumab in Treating Face/Head and Neck Involvement in Patients with Moderate-to-Severe Atopic Dermatitis
D1.449 - A Phase 2, Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of Briquilimab in Adults with Chronic Urticaria (Trial in Progress)
Pagination
Current page
1
Page
2
Next page
Next
Last page
Last
Download the app
The congress at your fingertips
Available on
Download